Herbert Irving Comprehensive Cancer Center
Investigator
Jennifer Amengual, MD
Email
jea2149@cumc.columbia.edu

Dr. Amengual is an Assistant Professor of Medicine and Developmental Therapeutics. Her research goals are focused on developing targeted therapies for the treatment of lymphoma. As a physician-scientist, she aims to directly translate observations and concepts developed in the laboratory to patient care.


Clinical Studies Managed By This Investigator:
Condition Study Title
Lymphoma [ CLOSED ] Study for patients with newly diagnosed Mantle Cell Lymphoma using study drug (BTK Inhibitor)
Lymphoma [ CLOSED ] Study of Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Subjects with Hodgkin Lymphoma
Cancer Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Lymphoma Study of Nivolumab Plus Standard Chemotherapy in Comparison to Brentuximab Vedotin Plus Standard Chemotherapy for Advanced Hodgkin Lymphoma
Lymphoma Study of Tazemetostat or Placebo with Lenalidomide plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Lymphoma Study of CC-486 (Oral Azacitidine) Alone or in Combination with Chemo in Participants with Diffuse Large B Cell Lymphoma (DLBCL) (Ages 75+)
Lymphoma Study of Duvelisib or Azacitidine in Addition to Chemotherapy in Patients with Peripheral T-Cell Lymphoma (PTCL)